Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 47 of 47 matching drugs for THRB — including drugs targeting any of its 19 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dextrothyroxine THRB Direct yes 0
dextrothyroxine sodium THRB Direct yes 0
levothyroxine THRB Direct yes 0
levothyroxine sodium THRB Direct yes 0
liothyronine THRB Direct yes 0
liothyronine sodium THRB Direct yes 0
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
pharmacological study, romidepsin HDAC4 SSL via HDAC4 2
adjuvant therapy, temozolomide, valproic acid, radiation therapy PPARG SSL via PPARG 1
adriamycin, cyclophosphamide, vindesine, valproic acid PPARG SSL via PPARG 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
curcumin PPARG SSL via PPARG 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy PPARG SSL via PPARG 1
glipizide PPARG SSL via PPARG 1
medical cannabis PPARG SSL via PPARG 1
nabiximols, temozolomide, nabiximols-matched placebo PPARG SSL via PPARG 1
pioglitazone, pioglitazone PPARG SSL via PPARG 1
porfimer sodium LDLR SSL via LDLR 1
porfimer sodium, adjuvant therapy, conventional surgery LDLR SSL via LDLR 1
porfimer sodium, endoscopic ultrasonography, photodynamic therapy, gemcitabine hydrochloride LDLR SSL via LDLR 1
romidepsin HDAC4 SSL via HDAC4 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule HDAC4 SSL via HDAC4 1
romidepsin, laboratory biomarker analysis HDAC4 SSL via HDAC4 1
sorafenib tosylate, valproic acid, sildenafil citrate PPARG SSL via PPARG 1
sulfasalazine PPARG SSL via PPARG 1
valproic acid PPARG SSL via PPARG 1
valproic acid, bevacizumab, radiation therapy PPARG SSL via PPARG 1
valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine PPARG SSL via PPARG 1
balsalazide PPARG SSL via PPARG yes 0
balsalazide disodium PPARG SSL via PPARG yes 0
belinostat HDAC4 SSL via HDAC4 yes 0
belinostat HDAC7 SSL via HDAC7 yes 0
bezafibrate PPARG SSL via PPARG yes 0
mesalamine PPARG SSL via PPARG yes 0
olsalazine PPARG SSL via PPARG yes 0
olsalazine sodium PPARG SSL via PPARG yes 0
panobinostat HDAC4 SSL via HDAC4 yes 0
panobinostat HDAC7 SSL via HDAC7 yes 0
panobinostat lactate HDAC4 SSL via HDAC4 yes 0
panobinostat lactate HDAC7 SSL via HDAC7 yes 0
pioglitazone PPARG SSL via PPARG yes 0
pioglitazone hydrochloride PPARG SSL via PPARG yes 0
romideps HDAC4 SSL via HDAC4 yes 0
romideps HDAC7 SSL via HDAC7 yes 0
rosiglitazone PPARG SSL via PPARG yes 0
rosiglitazone maleate PPARG SSL via PPARG yes 0
troglitazone PPARG SSL via PPARG yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.